Treatment of pediatric XXXX with @entity1771 .

@entity1 @entity410 @entity520 @entity1771 @entity1875 @entity1363 @entity159
OBJECTIVE: We evaluated a @entity1771 (TPM) regimen for treating @entity159 in the largest pediatric series, reported to date. METHODS: Fourteen @entity1 received TPM via the nasogastric route. Initially, all @entity1 received TPM as a 5 mg/kg loading dose followed by 5 mg/kg/day in two doses as maintenance. Thereafter, @entity1 were divided into three groups based on the response to TPM therapy and @entity410 cessation time (full responder, partial responder, and nonresponder). Four @entity1 received only thiopental, two received thiopental, and high-dose @entity1363 , one received thiopental, high-dose @entity1363 , and @entity1875 , two received only @entity1875 , one received @entity1875 , and high-dose @entity1363 and four @entity1 were on a high-dose @entity1363 infusion. RESULTS: The median time to @entity410 cessation was 5.5 h (range 2-48 h). Nine @entity1 were full responders, three were partial responders, and two were nonresponders At follow-up, six @entity1 were weaned successfully from thiopental, two @entity1 from high-dose @entity1363 and three @entity1 from @entity1875 . Three @entity1 developed mild @entity520 during TPM theraphy. CONCLUSIONS: Most of the @entity1 responded to this treatment which was well tolerated. So we recommended its use for terminating @entity159 in @entity1 .
